InnoCare Pharma Limited (SHA:688428)

Market Cap	33.50B
Revenue (ttm)	1.32B
Net Income (ttm)	-208.88M
Shares Out	n/a
EPS (ttm)	-0.13
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	6,301,173
Average Volume	9,598,877
Open	27.77
Previous Close	27.74
Day's Range	27.70 - 28.93
52-Week Range	10.65 - 34.02
Beta	0.98
RSI	52.01
Earnings Date	Nov 14, 2025

About InnoCare Pharma

InnoCare Pharma Limited, a biopharmaceutical company, engages in discovering, developing, and commercializing drugs for the treatment of cancer and autoimmune diseases in China. The company develops Orelabrutinib, an BTK inhibitor to treat patients with relapsed and/or refractory (r/r) chronic lymphocytic leukemia, r/r mantle cell lymphoma, r/r Waldenstrom’s macroglobulinemia, r/r marginal zone lymphoma, r/r diffuse large B-cell lymphoma (DLBCL)- MCD, r/r central nervous system lymphoma, combo w/MIL-62, systemic lupus erythematosus, immune thro...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2015
• Employees: 939
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 688428

Financial Performance

In 2024, InnoCare Pharma's revenue was 1.01 billion, an increase of 36.68% compared to the previous year's 738.54 million. Losses were -440.63 million, -30.20% less than in 2023.